Table 3.
Allelic HR of all-cause and CVD mortality for rs10911021 in the two study cohorts and in the combined analysis
| JKS |
GMS |
JKS + GMS |
||||
|---|---|---|---|---|---|---|
| HR (95% CI) | P | HR (95% CI) | P | HR (95% CI) | P | |
| All-cause mortality | ||||||
| Model 1 | 1.32 (1.07–1.64) | 0.010 | 1.30 (1.01–1.69) | 0.044 | 1.32 (1.12–1.55) | 0.0011 |
| Model 2 | 1.33 (1.07–1.65) | 0.0093 | 1.32 (1.02–1.71) | 0.038 | 1.32 (1.12–1.56) | 0.0009 |
| Model 3 | 1.50 (1.19–1.88) | 0.0006 | 1.23 (0.95–1.60) | 0.12 | 1.35 (1.14–1.60) | 0.0005 |
| CVD mortality | ||||||
| Model 1 | 1.51 (1.12–2.04) | 0.0077 | ||||
| Model 2 | 1.50 (1.11–2.03) | 0.0085 | ||||
| Model 3 | 1.72 (1.24–2.38) | 0.0011 | ||||
Model 1, rs10911021; Model 2, rs10911021, sex, age, and race; Model 3, rs10911021, sex, age at study entry, race, BMI, HbA1c, CKD, microalbuminuria/macroalbuminuria, and glucose-lowering therapy.